GIBBSTOWN, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--EMD Chemicals, Inc. (EMD), a subsidiary of Merck KGaA, Darmstadt, Germany, and Epitome Biosystems, Inc, announced today that EMD has launched WideScreen™ EpiTag™ ERK Pathway Assays, the first wave of bead-based, multiplex assays using EpiTag™ Technology licensed from Epitome Biosystems. The new line of assays will enable researchers to make quantitative, highly multiplexed measurements of important cell targets, greatly facilitating drug discovery efforts.
